TMO Stock Analysis — Thermo Fisher Scientific

Sector: Healthcare

AI Verdict

TMO trades at 18.1x next year's earnings while analysts expect a 55.3% jump in EPS—this is cheap for the growth on offer if its entrenched lab supply position continues to deliver.

Competitive Moat

Thermo Fisher Scientific dominates life sciences tools and diagnostics through a vast portfolio of proprietary instruments, consumables, and services that create high switching costs for research and clinical labs. Its scale and integration across research, diagnostics, and bioproduction make it a critical supplier with entrenched customer relationships.

Summary

Thermo Fisher is on watch as analysts expect a massive 55.3% jump in earnings over the next year.

Where It Stands

TMO is up 19.74% over the past year, trades at 18.1x forward earnings (below the healthcare median of 22x), and shows an RSI of 67.0 signaling elevated pullback risk.

Key Metrics

RSI: 67 — Near Overbought
Trailing P/E: 28.0x
Forward P/E: 18.1x
PEG Ratio: 0.50
Earnings Growth: +0.6%
Revenue Growth: +0.1%
Market Cap: $189.8B
Dividend Yield: 0.00%
1-Year Return: 19.74%
52-Week High: $643.99
52-Week Low: $403.36

Analyst Consensus

29 Buy · 7 Hold · 0 Sell (36 analysts)

Bull Case

With forward EPS growth forecast at 55.3% and a forward P/E of 18.1x, you're paying a low price for unusually rapid earnings expansion.

Bear Case

An RSI of 67.0 means the stock is at elevated risk of a pullback, so a return to a sector-average 22x P/E would actually lift the price, but a dip to 15x would mean a 17% drop from here.

Catalyst to Watch

Watch for quarterly earnings beats or misses, as any deviation from the 55.3% EPS growth forecast will swing sentiment sharply.